Vivimed Labs is aiming to take advantage of global market potential for formulations post its acquisition of Spain-based active pharmaceutical ingredients maker, Uquifa. The company will facilitate Uquifa's active pharmaceutical ingredients' capacity, which will complement its formulations business with cost competitiveness.
Through shifting Uquifa's pharma ingredients production to India the Hyderabad-based company is going for backward integration. Its API facilities coming up at pharma special economic zone at Visakhaptanam and Bidar in Karnataka will help the company in formulations. Another plant to make finished dosages is also being set up exclusively for regulated markets at Choutuppal.
The combined investment in these plants is about Rs 190 crore. All of them should begin production by end of next financial year. The company expects to double its turnover to Rs 1,000 crore by end of next financial year with an equal share of specialty chemicals and pharmaceuticals in revenue.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1668.00 |
| Dr. Reddys Lab | 1232.25 |
| Cipla | 1228.90 |
| Zydus Lifesciences | 936.35 |
| Lupin | 2328.60 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: